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The immunoglobulin receptor glycoprotein (GP) VI is expressed on megakary-
ocytes and platelets. GPVI associates with the Fc receptor (FcR) γ-chain in the
membrane, and with the Src family kinases (SFK) Lyn and Fyn through its cytosolic
tail.1 Ligand binding clusters GPVI at the platelet surface promoting phosphoryla-
tion of the immunoreceptor tyrosine-based motif (ITAM) of the FcR γ-chain by
SFK.2–4 This results in the recruitment of Syk and formation of a LAT-based signalo-
some that activates PLCγ2 leading to an increase in Ca2+, activation of integrin and
secretion of granules.5
GPVI is widely known as a platelet activation receptor for fibrillar collagen.5
However, in recent years, GPVI has been shown to bind to additional ligands,
including subendothelial and plasma adhesive proteins such as laminins and fib-
rin,6–8 the hormone adiponectin and the transmembrane protein emmprin.9,10
Several of these interactions are relatively weak and of unclear significance. For
example, GPVI supports adhesion and efficient activation of platelets to collagen
Glycoprotein VI, a major platelet activation receptor for collagenand fibrin, is considered a particularly promising, safe antithrom-botic target. In this study, we show that human glycoprotein VI
signals upon platelet adhesion to fibrinogen. Full spreading of human
platelets on fibrinogen was abolished in platelets from glycoprotein VI-
deficient patients suggesting that fibrinogen activates platelets through
glycoprotein VI. While mouse platelets failed to spread on fibrinogen,
human-glycoprotein VI-transgenic mouse platelets showed full spreading
and increased Ca2+ signaling through the tyrosine kinase Syk. Direct bind-
ing of fibrinogen to human glycoprotein VI was shown by surface plas-
mon resonance and by increased adhesion to fibrinogen of human glyco-
protein VI-transfected RBL-2H3 cells relative to mock-transfected cells.
Blockade of human glycoprotein VI with the Fab of the monoclonal anti-
body 9O12 impaired platelet aggregation on preformed platelet aggre-
gates in flowing blood independent of collagen and fibrin exposure.
These results demonstrate that human glycoprotein VI binds to immobi-
lized fibrinogen and show that this contributes to platelet spreading and
platelet aggregation under flow.
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ABSTRACT
and fibrin but is only involved in post-adhesive events on
laminin.6,11 Determining the importance of the interaction
of GPVI with each ligand in mediating platelet activation
in vivo will require development of selective inhibitors.
GPVI is involved in arterial thrombosis and in several of
the more recently discovered roles of platelets, including
maintenance of vascular integrity at sites of inflammatory
challenge.12 We and others have reported that the absence
of GPVI reduces experimental thrombosis in mouse mod-
els of atherosclerotic plaque rupture13,14 and abolishes
occlusive thrombus formation following FeCl3 injury.15 In
contrast, the absence or blockade of GPVI has a relatively
minor impact on hemostasis in mice16 and patients defi-
cient in GPVI have a relatively mild bleeding diathesis.17–19
These results highlight that GPVI is a promising anti-
thrombotic target with inhibitors predicted to have a
minor effect on hemostasis.20
Following ligand binding, GPVI stimulates signals that
convert integrin aIIbβ3 from a low to a high affinity state
for fibrinogen and other physiological ligands.21 Ligand
engagement of integrin aIIbβ3 has been reported to gen-
erate outside-in signals that are similar to those of GPVI,
including activation of Src and Syk kinases, PLCγ2 and
Ca2+ mobilization.22–24 Paradoxically, however, human but
not mouse platelets generate extensive lamellipodial
sheets and stress fibers on fibrinogen whereas on colla-
gen, which stimulates similar signals, full spreading of
platelets is seen in both species.25 One explanation for
this difference is the presence of the low affinity immune
receptor, FcγRIIA, in the human but not the rodent
genome, as FcγRIIA-transfected transgenic mouse
platelets exhibit increased spreading and Syk activation
upon adhesion to fibrinogen, although the increase in
spreading is only partial.26–28 Outside-in signaling by
aIIbβ3 is also mediated by two conserved tyrosines pres-
ent in a NxxY motif in the integrin β3 intracytoplasmic
domain independent of Src and Syk activation. Mutation
of these two tyrosine residues to phenylalanine leads to
a re-bleeding diathesis that has been attributed to a
defect in clot retraction.29 This shows that engagement of
integrin aIIbβ3 leads to activation of multiple signaling
pathways. 
In the present study, we showed that full spreading of
human platelets on fibrinogen is abolished in patients
deficient in GPVI and that transgenic mouse platelets
expressing human GPVI, in contrast to wild-type
platelets, spread fully on fibrinogen. Direct binding of fib-
rinogen to human GPVI was demonstrated using human
GPVI-transfected cell lines and recombinant GPVI.
Inhibiting the binding of fibrinogen to GPVI limited
platelet aggregation under conditions that excluded
involvement of collagen and fibrin.
Methods 
Patients
Family 1 and family 2 are two families who are heterozygous or
homozygous for an adenine insertion in exon 6 of GP6 that gen-
erates a premature stop codon in position 242 of the protein.17
They have been described previously.30 Patient 3 is a 10-year old
boy suffering from an autoimmune disease with anti-GPVI anti-
bodies. The platelets of this patient do not aggregate to collagen
and GPVI is not detected at the platelet surface using flow cytom-
etry and western blot (data not shown).
Mice
Wild-type mice were generated from breeding of heterozy-
gotes or purchased from Harlan Laboratories (Hillcrest, UK) or
Charles River (Lyon, France). GPVI-/- mice were provided by Dr
Jerry Ware.31 Mouse platelets expressing human GPVI have
been described and characterized previously.32 Syk chimera
mice have been described previously.27 Ethical approval for ani-
mal experimentation was obtained from the French Ministry of
Research and UK Home Office in accordance with the
European Union guidelines, the Guide for the Care and Use of
Laboratory Animals.
Reagents
PRT-060318 was obtained from Caltag Medsystems
(Buckingham, UK), REOPRO from E. Lilly (Indianapolis, IN,
USA). Recombinant GPVI was made as described elsewhere.33
Fibrinogen was from Kabi (Bad Homburg, Germany) or from
ERL (South Bend, IN, USA). RAM.1 (anti-GPIbβ) was generated
in U949.34 The blocking Fab fragment of monoclonal antibody
directed against human GPVI, 9O12.2, and its humanized ver-
sion are referred to as 9O12 in this manuscript.35,36 All other
reagents were from previously described sources.11,37 The anti-
fibrin antibody 59D8 was obtained from CT Esmon (Oklahoma
Medical Research Foundation, OK, USA).38
Generation and characterization of RBL-2H3 cells 
The cDNA of WT human GPVI33 was inserted in pSRαNeo
between the 5’-XhoI and 3’-BamHI restriction sites. Rat
basophilic leukemia cells, RBL-2H3, were cultured in Dulbecco
modified Eagle medium supplemented with 10% fetal bovine
serum albumin and stably transfected with 1 μg of DNA corre-
sponding to the empty vector or WThGPVI vector mixed with
FuGENE6 (Roche, Boulogne-Billancourt, France) and selected in
growth medium containing G418 0.7%; 1 mg/mL geneticin
(GibcoBRL, Invitrogen, Cergy Pontoise). Cell surface expression
of recombinant GPVI and constitutively expressed integrin
aIIbβ3 was confirmed by flow cytometry and immunoblot
(data not shown). 
Cell adhesion to fibrinogen
LAB TEK 4 wells were coated with 400 μL/well of collagen
(50 µg/mL) or fibrinogen (100 μg/mL) overnight at 37°C. Wells
were saturated with human serum albumin (10 mg/mL) for 1 h
at 37°C. Trypsinised RBL cells (3x105 cells/mL) were incubated
with phosphate-buffered saline or 9O12 (50 μg/mL) and/or
REOPRO (40 μg/mL) for 15 min at 37°C. Subsequently, 100,000
cells were added to the wells (300 μL) for 1 h at 37°C. After
three washing steps, cells were fixed with 400 μL paraformalde-
hyde 4% for 20 min. Pictures were taken with an EVOS optic
microscope (x10). Actin was stained with Alexa-488-phalloidin
and the nucleus with DAPI.
Washed platelets
Human blood was taken from patients or from healthy
donors using 3.8% (v/v) sodium citrate (1:9) as the anticoagu-
lant. Human and mouse washed platelets were obtained by
centrifugation using prostacyclin (2.8 μmol/L) and resuspended
in modified Tyrode-HEPES buffer as described elsewhere.37,39
Platelet spreading
Platelet adhesion to immobilized fibrinogen was achieved as
described previously.37 Images of the platelets were obtained
with a Zeiss Axiovert 200 mol/L microscope or with a Leica
DMI400 microscope. Platelet surface area was analyzed using
ImageJ software (NIH, Bethesda, USA).
Fibrinogen, GPVI and platelet activation
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Western blotting
For stimulation on fibrinogen, washed platelets were pre-treat-
ed with 10 μmol/L indomethacin and 2 U/mL apyrase. Platelets
(1.5 mL containing 5x108/mL) were allowed to adhere to 10 cm
dishes coated with 100 μg/mL fibrinogen or heat-inactivated
bovine serum albumin for 45 min at 37°C. Non-adherent platelets
were removed and lysed by addition of 2X lysis buffer (150
mmol/L NaCl, 10 mmol/L Tris, 1 mmol/L EGTA, 1 mmol/L EDTA,
1% NP-40; pH 7.4, plus 1.25 mmol/L Na3VO4, 50 μg/mL AEBSF,
2.5 μg/mL leupeptin, 2.5 μg/mL aprotinin and 0.25 μg/mL pep-
statin). Adherent platelets were washed twice with Tyrode buffer
then lysed with 1X lysis buffer on ice for 15 min before scraping.
Proteins were immunoprecipitated with a-Syk antibody and pro-
tein A-sepharose beads for 2 h. The beads were washed, proteins
eluted in sodium dodecyl sulfate (SDS) sample buffer, separated
by SDS-polyacrylamide gel electrophoresis (PAGE), electro-trans-
ferred, and western blotted with the stated antibodies. For whole
platelet lysates, washed platelets (5x108/mL) were lysed directly
with an equal volume of 2xSDS sample buffer, separated by SDS-
PAGE, electro-transferred, and western blotted with the stated
antibodies.
Ca2+ assay and in vitro perfusion assay 
Intraplatelet Ca2+ concentrations following platelet adhesion to
fibrinogen were measured using a dual-dye ratiometric method
and hirudinated blood perfusion was performed as previously
described.40 Three-dimensionsal reconstructed images were
obtained using the 3D module of Leica LAS X software.
Solid-based binding assay
Binding studies were performed with the recombinant proteins,
GPVI-Fc fusion (dimer) and GPVI-His tagged (monomer). Cover
slips were coated with collagen or fibrinogen overnight at 4°C.
The plates were blocked with 3% bovine serum albumin – phos-
phate-buffered saline for 1 h and washed prior to addition of
monomeric or dimeric GPVI at a concentration of 100 nmol/L for
1 h. After washing, 4 μg/mL of secondary antibodies, horseradish
peroxidase (HRP)-conjugated goat anti-human IgG Fc or HRP-con-
jugated anti-His Tag, were added for 1 h. GPVI binding was
detected using 3,3′,5,5′-tetramethylbenzidine. The reaction was
stopped with H2SO4 (2 mol/L) and absorbance was measured at
450 nm with a spectrofluorometer. 
Surface plasmon resonance
Surface plasmon resonance was performed on a Pioneer plat-
form from PALL® FortéBio® (Portsmouth, UK). IF-1 purified fib-
rinogen was diluted to 100 μg/mL using 10 mmol/L NaAc pH 5.0.
IF-1 fibrinogen was adsorbed to the chip surface via amine cou-
pling to a level of 3825 resonance units (RU) at flow-cell 1 and
3423 RU on flow-cell 3. Flow-cell 2 was activated using amine
coupling and blocked using 1 mol/L ethanolamine and was the
designated reference channel. GPVI analytes were dialysed and
diluted to 1 µmol/L using the same batch of running buffer as used
for the blanks. Analytes were injected using the OneStep® titration
function at a flow rate of 30 μL/min with a 100% loop-inject and
400 s dissociation. The chip surface was regenerated by flushing
with 1 mol/L NaCl at 60 μL/min for 10 s, followed by a further 400
s dissociation. Qdat data analysis software (PALL® FortéBio®, UK)
was used to analyze the data. Binding data were fitted using a one
site KA/KD model and analyte aggregation parameters adjusted per
binding curve according to goodness of fit and curve type. 
Statistics
The statistical analyses were performed using the GraphPad
Prism program, version 5.0 (Prism, GraphPad, LaJolla, CA, USA).
The values are indicated as mean ± standard error of the mean
(SEM). The statistical analysis is described in the Figure legends. 
Results
Abolition of spreading on fibrinogen in glycoprotein 
VI-deficient human platelets
Human platelets undergo robust spreading on immobi-
lized fibrinogen, generating lamellipodial sheets and stress
fibers.41 This is illustrated in Figure 1A with over 90% of
platelets from a control donor undergoing full spreading
on fibrinogen over 30 min; the small number of partially-
spread platelets most likely represent newly adhered cells.
In 2013, Matus et al. described four unrelated families with
index cases who are homozygous for an adenine insertion
in exon 6 of human GP6, which leads to a premature ‘stop
codon’ in position 242 prior to the transmembrane
domain.17 All four homozygous patients lack expression of
GPVI on their platelets and heterozygous relatives express
approximately 50% of the receptor. Since then, two fur-
ther unrelated families with the same mutation have been
identified by the same group and also been shown to lack
surface expression of GPVI with absent platelet aggrega-
tion to collagen.30 Unexpectedly, in studying platelets from
two unrelated index cases in these families, we observed
reduced adhesion on immobilized fibrinogen and a failure
to form lamellipodial sheets and stress fibers (Figure 1A).
The absence of GPVI was confirmed by flow cytometry
and by abolition of aggregation to collagen but not to
other agonists in both cases30 (data not shown). In contrast,
spreading and adhesion of platelets from heterozygote
carriers from each family and platelets from a control were
similar (Figure 1A). The same result was also seen in a
patient with an auto-immune thrombocytopenia associat-
ed with the absence of GPVI expression (Figure 1Bi).
Adhesion of platelets was blocked by the aIIbβ3 receptor
antagonist, REOPRO (Figure 1B), as previously shown in
controls. These results demonstrate that adhesion of
human platelets on fibrinogen is critically dependent on
integrin aIIbβ3 with a minor contribution from GPVI, but
that full spreading requires GPVI.
Mouse platelets expressing human glycoprotein VI
undergo full spreading on fibrinogen
Mouse platelets adhere and undergo limited spreading
on human or mouse fibrinogen, forming filopodia and
limited lamellipodia but not stress fibers (Figure 2A). A
similar response is seen in platelets deficient in GPVI
(Figure 2A), whereas adhesion is abolished in the absence
of the integrin β3-subunit (Figure 2B). A similar level of
adhesion is seen in human GPVI transgenic mouse
platelets but is associated with the formation of lamellipo-
dial sheets and stress fibers (Figure 2C). These results
demonstrate that full spreading but not adhesion of mouse
platelets is dependent on human GPVI and not mouse
GPVI. One potential explanation for these results is that
human but not mouse GPVI is able to bind to fibrinogen
and mediate platelet activation.
Fibrinogen binds to monomeric human glycoprotein VI 
To test whether fibrinogen is able to bind to GPVI,
increasing concentrations of recombinant soluble GPVI
extracellular domain, expressed either as a monomer
(GPVI-ex) or dimer (GPVI-Fc), was flowed over immobi-
P.H. Mangin et al.
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lized fibrinogen and binding monitored by surface plas-
mon resonance. As shown in Figure 3A, clear binding of
monomeric GPVI (ka = 1.17 ± 0.01 x 104 M-1s-1) was
observed with a kd of 3.94 ± 0.01 x 10-3 s-1. Binding was fit-
ted to a single site with an equilibrium dissociation con-
stant (KD) of 336 ± 1 nmol/L. In contrast, binding of dimer-
ic GPVI to fibrinogen was not detected at concentrations
up to 1 μmol/L (Figure 3Ai). In a second approach, fibrino-
gen was immobilized on a plastic surface and a solid
phase binding assay was performed. There was increased
binding of monomeric GPVI, but not dimeric GPVI, which
was inhibited by D-dimer (Figure 3Aii) where the binding
motif in fibrin resides.30 To further investigate the ability
of GPVI to bind to fibrinogen, we transfected rat RBL-2H3
basophilic cells, which constitutively express integrin
aIIbβ3 at low levels, with human GPVI and studied adhe-
sion to immobilized fibrinogen. We observed a 3-fold
increase in adhesion of GPVI-transfected cells to fibrino-
gen and to collagen relative to the adhesion of mock-trans-
fected control cells (Figure 3Bi, ii). RBL-2H3 cells express-
ing human GPVI also formed stress fibers upon adhesion
to fibrinogen. The human GPVI-blocking monoclonal
antibody 9012 Fab blocked the increase in adhesion.
Blocking the integrin aIIbβ3 with REOPRO reduced cell
adhesion to immobilized fibrinogen to the same level as
9O12 Fab, with no further inhibition in the presence of
both inhibitors (data not shown), indicating the presence of
additional binding proteins for fibrinogen in the adherent
cell line although binding to these was not sufficient to
induce spreading (Figure 3Biii and not shown). These
results demonstrate that GPVI binds to immobilized fib-
rinogen and is able to contribute to cell adhesion.
Spreading of human platelets but not mouse platelets
is dependent on Syk
The formation of lamellipodial sheets and stress fibers
in human platelets on fibrinogen and collagen is blocked
by the inhibitors of Src and Syk tyrosine kinases, PP2 and
PRT060318, respectively (Figure 4Ai & ii). Adhesion of
human platelets to fibrinogen induces phosphorylation of
Syk which co-precipitates with the phosphorylated FcR γ-
chain (Figure 4Aiii). These results provide further evidence
of GPVI activation in human platelets by immobilized fib-
rinogen. In contrast, the morphological modifications of
Fibrinogen, GPVI and platelet activation
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Figure 1. Glycoprotein VI supports
platelet adhesion and spreading on
immobilized fibrinogen. (A, B) Washed
human platelets were allowed to
adhere to immobilized fibrinogen (10
μg/mL) for 30 min. (A)(i).
Representative epifluorescence
images of fibrinogen-adherent
platelets from healthy donors (Control)
or members of a family with a mutation
in the GP6 gene (Heterozygotes: Family
1 +/-; homozygotes: Family 1 -/-). Scale
bars represent 10 μm. (A)(ii). Bar graph
representing the percentage of
platelets spreading on fibrinogen.
Spreading is expressed as the
mean±SEM in five random fields, in
two separate experiments (one-way
ANOVA, Kruskal-Wallis post-hoc test,
***P<0.0002; ****P<0.0001).
(A)(iii). Bar graph representing the
number of platelets adhering to immo-
bilized fibrinogen per mm² of a control
(Control) and two families with a muta-
tion in the GP6 gene. Adhesion is
expressed as mean±SEM in five ran-
dom fields, in two separate experi-
ments (one-way ANOVA, Kruskal-Wallis
post-hoc test, **P<0.002;
****P<0.0001). (B). Washed platelets
from a control or a patient with an
immune thrombocytopenic purpura
presenting with undetectable levels of
GPVI on platelets (Patient 3) were
allowed to adhere to fibrinogen (100
μg/mL). (B)(i). Representative epifluo-
rescence images of washed platelets
from patient 3 adhering to immobilized
fibrinogen for 30 min, in the presence
or absence of REOPRO (40 μg/mL).
Scale bars represent 10 μm. (B)(ii). Bar
graph represents the number of
platelets adhering to fibrinogen per
mm2. Adhesion is expressed as
mean±SEM in eight random fields, in
two separate experiments.
A
B
mouse platelets on fibrinogen is blocked by the Src kinase
inhibitor PP2 but not by the Syk kinase inhibitor
PRT060318 (Figure 4B). Morphological changes of mouse
platelets on fibrinogen are also not altered in platelets
from irradiated mice transplanted with Syk-deficient fetal
liver (Figure 4B) or from PF4.Cre-Sykfl/fl mice (Online
Supplementary Figure S1). Western blotting for Syk con-
firmed lack of expression of the tyrosine kinase in the two
transgenic models (Figure 4B and not shown). Thrombin
stimulated full spreading of wild-type and Syk-deficient
platelets (Figure 4B). Formation of lamellipodia and stress
fibers in human GPVI transgenic mouse platelets was
blocked by PRT060318 (Figure 4C). The ability of Src and
Syk inhibitors to block spreading of human platelets and
human GPVI transgenic mouse platelets on fibrinogen is
consistent with platelet activation by GPVI. This is sup-
ported by demonstration of phosphorylation of the FcR γ-
chain. The limited spreading of mouse platelets on fibrino-
gen is mediated through a Src-dependent but Syk-inde-
pendent pathway. Together, these results support a model
in which immobilized fibrinogen activates human but not
mouse platelets through GPVI.
P.H. Mangin et al.
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Figure 2. Human but not mouse glyco-
protein VI supports platelet adhesion
and spreading on immobilized fibrino-
gen. (A). Washed platelets from wild-
type mice (WT mice), GPVI-deficient
mice (GPVI-/- mice) or from healthy
donors (Human) were allowed to adhere
to human or mouse fibrinogen (FGN) for
30 or 45 min, respectively, and fixed
with PFA and stained with Alex-488-
phalloidin (4 μg/mL). (A)(i).
Representative epifluorescence images
of washed platelets adhering to fibrino-
gen. Scale bars represent 10 µm. (A)(ii).
Bar graph representing the number of
platelets adhering to immobilized fib-
rinogen per mm². Adhesion is expressed
as mean±SEM in five random fields, in
three separate experiments (two-way
ANOVA, Bonferroni post-hoc test:
P>0.05). (A)(iii). Bar graph representing
the percentage of platelets spreading
on immobilized fibrinogen. Spreading is
expressed as the mean±SEM in five ran-
dom fields, in six separate experiments.
Significance was attained using a two-
way ANOVA, Bonferroni post-hoc test:
****P<0.001. (B). Washed control (WT)
or β3-deficient (β3-/-) platelets were
allowed to adhere to fibrinogen for 60
min, fixed with PFA and stained with
TRITC-phalloidin (2 μg/mL). (B)(i).
Representative epifluorescence images
of washed mouse platelets adhering to
fibrinogen. Scale bars represent 10 μm.
(B)(ii). Bar graph representing the num-
ber of platelets adhering to immobilized
fibrinogen per mm². Adhesion is
expressed as the mean±SEM in eight
random fields, in four separate experi-
ments (Mann-Whitney test,
**P<0.001). (C). Washed platelets from
wild-type mice (WT mice) or mice
expressing human GPVI (hGPVI mice)
were allowed to adhere to fibrinogen for
60 min, fixed with PFA and stained with
TRITC-phalloidin (2 μg/mL). (C)(i).
Representative epifluorescence images
of washed platelets adhering to fibrino-
gen. Scale bars represent 10 μm. (C)(ii).
Bar graph (left) representing the num-
ber of platelets adhering to immobilized
fibrinogen per mm². Adhesion is
expressed as the mean±SEM in eight
random fields, in four separate experi-
ments (Mann-Whitney test, P>0.05).
Bar graph (right) representing the per-
centage of platelets spreading on immo-
bilized fibrinogen. Spreading is
expressed as the mean±SEM in eight
random fields, in four separate experi-
ments (Mann-Whitney test,
**P<0.001).
A
B
C
Fibrinogen stimulates an increase of Ca2+ in human
glycoprotein VI-transgenic mouse platelets
The observation that platelets expressing human but
not mouse GPVI undergo full spreading suggests that sig-
nals from human GPVI are of significance. To investigate
this, a dual-dye Ca2+ assay was used to monitor cytoplas-
mic Ca2+ levels as a marker of PLCγ2 activation. Analysis
of single platelet Ca2+ profiles by confocal microscopy
highlighted that signals generated on fibrinogen are com-
posed of Ca2+ spikes (Figure 5A). The number of Ca2+
spikes in mouse platelets expressing human GPVI was sig-
nificantly increased relative to the number in wild-type
platelets and was blocked in the presence of PRT-060318
(Figure 5Ai-ii) highlighting the critical role of Syk in Ca2+
mobilization. These results demonstrate that human GPVI
stimulates Ca2+ signaling in fibrinogen-adherent mouse
platelets.
Fab 9O12 blocks aggregate growth of humanized 
glycoprotein VI mouse platelets
Fibrinogen plays a critical role in hemostasis and arterial
thrombosis through crosslinking of platelets in the grow-
ing thrombus. In addition, we now show that fibrinogen
induces platlet activation by GPVI. To establish whether
Fibrinogen, GPVI and platelet activation
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Figure 3. Monomeric but not dimeric GPVI binds to
immobilized fibrinogen and supports cellular adhe-
sion. (A)(i). IF-1 purified fibrinogen was immobilised
to a COOH-V chip surface using amine coupling
covalent linkage, to a level of 3,825 RU. Monomeric
or dimeric GPVI was titrated over three to four orders
of magnitude across the chip surface to a maximum
of 1 µmol/L, generating a single binding curve (1 RU
represents the binding of approximately 1 pg/mm2
protein). The graphs shown are representative of
three repeats and the KD is expressed as mean ±
SEM. (A)(ii). Solid-phase binding assays were per-
formed in Nunc maxisorb 96-well plates coated
overnight with BSA and fibrinogen (FGN).
Monomeric or dimeric GPVI (100 nmol/L) was incu-
bated as described. Bound GPVI was detected using
HRP-coupled to an anti-6×His monoclonal antibody
for monomeric GPVI or an anti-human IgG for dimer-
ic GPVI. The histogram (mean ± SD) shows the
results from five independent experiments.
Significance was determined using a one-way
ANOVA, Dunnett post-hoc test : *P<0.05. (B). RBL-
2H3 cells (3x105 cells/mL; 300 μL) transduced with
an empty vector (RBL-2H3 Ctrl) or with human full-
length GP6 cDNA (RBL-2H3 huGPVI) were pre-incu-
bated with PBS, REOPRO (20 μg/mL), and 9O12 (50
μg/mL) and allowed to adhere to immobilized fib-
rinogen for 1 h at 37°C, in 5% CO2. After three gentle
washing steps, cells were permeabilised with TRI-
TON x100 0.2% and stained with Alexa-568 phal-
loidin (1.5 U/mL). (B)(i). Representative epifluores-
cence images of RBL cells adhering to immobilized
fibrinogen. (B)(ii). and (B)(iii). Cells were manually
counted in six to eight different experiments
(*P<0.05 Mann Whitney t-test in (ii) and one-way
ANOVA was followed by the Bonferroni multiple com-
parison test).
A
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activation of GPVI by platelet-bound fibrinogen partici-
pates in platelet aggregation we performed an in vitro flow
adhesion assay under conditions that prevent activation of
GPVI by collagen and by fibrin. To achieve this, we gener-
ated a platelet aggregate over type I fibrillar collagen using
hirudin-treated blood to prevent formation of fibrin. We
then perfused additional blood from the same donor over
the aggregate at a wall shear rate of 300 s-1 in the presence
or absence of the Fab fragment of the GPVI blocking mon-
oclonal antibody 9O12. As expected, we were unable to
detect the presence of fibrin in the aggregate using a spe-
cific antibody (data not shown). The aggregate continued to
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Figure 4. Syk promotes platelet spreading
on fibrinogen downstream of glycoprotein
VI but not in integrin aIIbβ3 outside-in sig-
naling.  Washed human platelets, or
washed platelets from wild-type mice (WT
mice), Syk chimera mice (Syk chimera mice)
and mice expressing human GPVI (hGPVI
mice) were allowed to adhere to fibrinogen
or to collagen in the presence of either the
Src inhibitor PP2 (20 μmol/L), the Syk
inhibitor (5 μmol/L), thrombin (0.1 U/mL),
or vehicle control, for 30 min (human
platelets) or 45 min (mouse platelets) at
37°C followed by fixation with PFA. (A)(i).
Representative DIC images of human
platelets adhering to fibrinogen or collagen.
Scale bars represent 5 μm. (A)(ii). Bar graph
representing the surface area of platelets
spreading on fibrinogen. Spreading is
expressed as the mean±SEM in five or more
random fields, in three separate experi-
ments. Significance was determined by one-
way ANOVA and Bonferroni multiple compar-
ison test: *P<0.01. (A)(iii) Representative
western blot from human platelets following
adhesion to fibrinogen. Following immuno-
precipitation of Syk, proteins were separat-
ed by sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis and western blot
for phosphotyrosine. Membranes were then
stripped and reprobed for Syk to confirm
equal protein loading.  Blots are representa-
tive of three separate experiments. (B)(i).
Representative DIC images of mouse
platelets adhering to fibrinogen. Scale bars
represent 5 μm. (B)(ii). Bar graph represent-
ing the surface area of platelets spreading
on fibrinogen. Spreading is expressed as
the mean±SEM in five or more random
fields, in three separate experiments.
Significance was determined using one-way
ANOVA, with the Bonferroni post-hoc test:
*P<0.05, **P<0.001. (B)(iii). Expression of
Syk was measured by western blotting
platelet whole-cell lysates with an a-Syk
antibody. Membranes were then stripped
and reprobed with an anti-a-tubulin anti-
body to confirm equal protein loading. Blots
are representative of three separate experi-
ments. (C)(i). Representative epifluores-
cence images of mouse platelets adhering
to fibrinogen. Scale bars represent 10 µm.
(C)(ii). Bar graph representing the surface
area of platelets spreading on fibrinogen.
Spreading is expressed as the mean±SEM
in eight random fields, in five separate
experiments (Mann-Whitney test,
**P<0.01).
B
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grow in the presence of a Fab control but was dramatically
inhibited in the presence of Fab 9O12 (Figure 6A and
Online Supplementary Figure S2). In contrast, and as previ-
ously shown, blockade of GPVI did not impair aggrega-
tion measured by light transmission aggregometry in
response to ADP, U46619 and thrombin.35 These results
demonstrate a critical role for GPVI in aggregate growth
under flow when the roles of collagen and fibrin are negat-
ed. In contrast, fibrinogen does not induce activation of
platelets in suspension either because the interaction is
dependent on activation of integrin aIIbβ3 or because  it
cannot crosslink GPVI.  
Discussion
In this study we show that human GPVI binds to immo-
bilized fibrinogen and that this leads to intracellular sig-
nals, which drive the formation of lamellipodial sheets
and stress fibers in human platelets and in human GPVI-
expressing mouse platelets. This explains the previously
paradoxical observation that only human platelets form
lamellipodial sheets and stress fibers on a fibrinogen sur-
face, despite mouse platelets being able to form both actin
structures in the presence of G protein-coupled receptor
agonists such as thrombin. We also show that the interac-
tion of fibrinogen with GPVI is important for aggregate
growth providing a new understanding of hemostasis and
thrombosis. 
We recently identified fibrin as a novel ligand for
GPVI7,8,42 and have shown that binding resides in the D-
dimer region.30 The observation that fibrinogen also acti-
vates GPVI should not, therefore, be a surprise.
Nevertheless, this was unexpected and came from the
observation that human platelets deficient in GPVI adhere
to but do not spread on fibrinogen. This raises the ques-
tion as to why this has been previously overlooked. One
reason is that mouse platelets do not spread on fibrinogen
and thus there is no defect in the absence of GPVI. A sec-
ond reason is the low level of phosphorylation of the FcR
γ-chain induced by fibrinogen in human platelets relative
to that by collagen and other GPVI-agonists. This may
reflect the extent to which each ligand is able to cluster
GPVI and, in the case, of fibrinogen, the dependency on
the interaction with integrin aIIbβ3. A third reason is that
fibrinogen binds selectively to monomeric GPVI whereas
the original binding studies were performed with dimeric
GPVI.7,8 It is worth noting that we have reported a reduced
number of dimers on immobilized fibrinogen relative to
collagen.42
Adhesion of human platelets to fibrinogen is dependent
on integrin aIIbβ3.  At present, it is not known whether
binding to integrin aIIbβ3 is critical for activation of GPVI
or simply to promote adhesion such that activation of
GPVI can occur. As a dimer, fibrinogen should be able to
bind two GPVI monomers, but alternatively the interac-
tion with integrin aIIbβ3 may be required to support acti-
vation of monomeric GPVI. A similar role for an integrin
in the activation of an ITAM receptor has been reported in
other hematopoietic cells with the postulate that the inte-
grin and the ITAM receptor would be associated via a link-
er protein.43
Fibrinogen is present in whole blood at a concentration
of 2 - 4 mg/mL but does not induce platelet activation.
This may be explained by an inability of soluble fibrino-
gen to bind GPVI in suspension due to conformational dif-
ferences between circulating and immobilized fibrinogen.
Alternatively it may be due to the inability of the dimeric
fibrinogen to cluster GPVI on the platelet surface in sus-
pension or because of a dependency on binding to integrin
aIIbβ3. While the affinity of fibrinogen for GPVI is in the
range of that for collagen for GPVI,44,45 we have shown that
fibrinogen (and fibrin) bind selectively to monomeric
GPVI and this would not be sufficient to induce activation
because of the absence of crosslinking. The reason why
human platelets, but not mouse platelets, spread on fib-
rinogen is unclear. Based on the fact that human and
mouse GPVI share 64% homology,33 one could imagine
that only human GPVI binds to fibrinogen or that both
bind to this adhesive protein but only human GPVI is able
to promote activation. 
GPVI is primarily known as the major signaling receptor
for collagen. However, in recent years, GPVI has been
shown to bind to other ligands including laminin, the
transmembrane protein emmprin, adiponectin, histones
and fibrin.6-8,10,47 The physiological significance of many of
these interactions is uncertain, in part because of their low
affinity or because of whether they acutally occur in vivo.
The interaction that has received the greatest attention is
that with fibrin which lies at the interface of the core and
shell of the growing platelet aggregate.7,8 This interaction
Fibrinogen, GPVI and platelet activation
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Figure 5. Human glycoprotein VI, but not integrin aIIbβ3 plays a major role in
the regulation of the calcium signaling after platelet adhesion to fibrinogen.
Washed platelets from wild-type (WT) or mice expressing human GPVI (hGPVI)
were loaded with Oregon-green Bapta-1-AM and Calcein red orange and
deposited on immobilized fibrinogen (100 μg/mL). Modifications in ﬂuores-
cence of individual adherent platelets were monitored for 7 min by confocal
microscopy and the Ca2+ concentrations were determined as detailed in the
Methods section. (A)(i). Typical time-course Ca2+ proﬁle of one representative
platelet adhering to fibrinogen. (A)(ii). Dot plot representing the number of cal-
cium spikes over a period of 5 min. Each point represents an individual
platelet. The results are presented as the mean±SEM of five independent
experiments (one-way ANOVA, Bonferroni post-hoc test, ***P<0.001).
A
takes place at a critical checkpoint in aggregate consolida-
tion and aggregate growth. Thus, GPVI has the potential
to both initiate and propagate thrombus formation
through interactions with collagen and fibrin and, it
appears now, also with fibrinogen. Moreover, while colla-
gen and fibrin are localized at the base of the thrombus
and in the core, respectively, fibrinogen is found through-
out the aggregate. This suggests a model in which throm-
bus growth could be sustained by GPVI/fibrinogen, poten-
tially in association with other adhesive proteins. Indeed,
in addition to fibrinogen other adhesive proteins such as
von Willebrand factor and fibronectin have been shown to
support thrombus growth.47–50 Whether these proteins par-
ticipate in GPVI-mediated platelet aggregation is unclear
since von Willebrand factor is not known to be a ligand of
GPVI and fibronectin does not directly promote platelet
adhesion and activation through GPVI.51 Selective inhibi-
tion of the interaction of GPVI with collagen, fibrinogen
and fibrin is required to establish their respective contribu-
tions to platelet activation in hemostasis and thrombosis.  
The discovery that GPVI initiates and propagates
platelet aggregation at sites of vessel injury suggests a
major role in hemostasis and thrombosis. Paradoxically,
however, mice and humans deficient in GPVI only have
at most a mild bleeding diathesis, which in the case of
humans may be due to additional confounders such as a
low platelet count as seen in patients with immune-
induced thrombocytopenia caused by antibodies to
GPVI. The relatively minor role of GPVI in hemostasis
can be explained by redundancy in pathways of platelet
activation, with the GPIb-von Willebrand factor axis ini-
tiating hemostasis, and ADP, thromboxane and thrombin
inducing powerful activation. Additionally, the reactive
fibrillar type I and III collagen present in deeper layers of
the vessels would limit the role of GPVI in the hemosta-
sic response following superficial injury. On the other
hand, the discovery that fibrin and immobilized fibrino-
gen activate GPVI may be of significance at sites of fib-
rinogen deposition or fibrin formation in diseased vessels
following inflammation or loss of vascular integrity. The
ability of fibrin and immobilized fibrinogen to activate
GPVI may also reflect yet-to-be-discovered new roles for
GPVI.  
In conclusion, in the present study, we have identified
immobilized fibrinogen as a novel activator of human but
not mouse GPVI and have shown that this interaction
supports platelet aggregation under flow. This further
emphasizes the contribution of GPVI to platelet activation
in thrombosis. 
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Figure 6. Blockade of human glycoprotein VI limits platelet accumulation to a growing aggregate. (A)(i). Hirudinated human whole blood labeled with DIOC6 (1
μmol/L) was perfused over immobilized collagen (200 μg/mL) to preform aggregates for 2 min 30 s, before perfusing hirudinated blood from the same donor in the
presence of the Alexa Fluor 647-conjugated monoclonal antibody against GPIbβ (5 μg/mL) and with a Fab control (Control) or the blocking anti-GPVI antibody 9O12
(50 μg/mL). (A)(i). Representative 3D reconstructions from confocal images of aggregates obtained after 7 min 30 s of blood perfusion at 300 s-1. Preformed aggre-
gates are represented in gray, aggregates formed in the presence of a Fab control are represented in red and aggregates formed in the presence of the Fab 9O12
are depicted in orange. (A)(ii). Bar graph representing the volume of the platelet aggregates (mean±SEM) in eight random fields, in six separate experiments per-
formed with different blood donors (Mann-Whitney test, ***P<0.001). The gray, red and orange colors represent the volume of the preformed aggregates, the aggre-
gates formed in the presence of a Fab control and the aggregates formed in the presence of the Fab 9O12, respectively.
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